Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Jascayd (nerandomilast) is an oral PDE4B inhibitor developed for progressive lung scarring conditions, offering antifibrotic and immunomodulatory effects through a distinct mechanism from existing antifibrotic therapies.
Jascayd is FDA-approved for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, and separately for the treatment of progressive pulmonary fibrosis (PPF) in adults. It has been studied both alone and alongside background antifibrotic treatment (nintedanib or pirfenidone).
Nerandomilast selectively inhibits the PDE4B isoenzyme, preferentially over PDE4A, PDE4C, and PDE4D. This elevates intracellular cAMP levels and reduces the expression of profibrotic growth factors and inflammatory cytokines that are overexpressed in IPF and PPF, helping to slow disease progression.
The recommended dose is 18 mg orally twice daily, approximately 12 hours apart, with or without food; tablets can be swallowed whole or dispersed in water for patients who have difficulty swallowing. The dose is reduced to 9 mg twice daily when used with strong CYP3A inhibitors; no adjustment is needed with moderate or weak CYP3A inhibitors, as determined by the treating pulmonologist.
In the FIBRONEER-IPF clinical trial (1,177 patients randomized to Jascayd 18 mg, 9 mg, or placebo, with or without background antifibrotic therapy), the following safety considerations were identified.
Diarrhea was the most common adverse reaction leading to treatment discontinuation, occurring in 6% of patients on the 18 mg dose and 2% on the 9 mg dose. Monitor for persistent or severe diarrhea and manage per the treating physician's guidance.
Depression-related adverse events, including depressed mood, were reported in clinical trials. Patients and caregivers should report any new or worsening mood changes promptly.
Concomitant use with strong CYP3A inhibitors requires a reduced dose. Discuss all current medications with the treating physician before starting Jascayd.
As with many systemic therapies, discuss pregnancy planning and contraception with the treating physician before starting treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Jascayd (nerandomilast) is manufactured by Boehringer Ingelheim, offering a new PDE4B-targeted mechanism for both idiopathic and progressive pulmonary fibrosis.
Import of Jascayd through a Named Patient Program requires a valid prescription from the treating pulmonologist, confirmation of IPF or PPF diagnosis, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Jascayd directly from Boehringer Ingelheim's authorized supply chain to ensure product authenticity and regulatory compliance.
Jascayd is sourced through verified, GDP-compliant channels from Boehringer Ingelheim's authorized supply chain to ensure authenticity and quality.
Jascayd tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F), in the original container to protect from light.
Once sourced, Jascayd is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Jascayd through NPP's regulated import pathway, with pulmonology specialists in major cities supporting the treatment process.
Leading pulmonology centers in Mumbai support IPF and PPF diagnosis and treatment coordination for Jascayd access.
Delhi's major hospitals assist patients with diagnostic confirmation and prescription support for Jascayd.
Bangalore's specialist network offers access to pulmonary fibrosis treatment planning for eligible patients.
Chennai-based specialists coordinate Jascayd access alongside comprehensive respiratory care.
Hyderabad's care institutions support patients pursuing Jascayd therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Jascayd.
Pune-based specialists assist with diagnosis confirmation and Jascayd treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Jascayd.
Kochi's specialist units assist patients with the documentation needed for Jascayd access.
Chandigarh's care centers support Jascayd treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Jascayd access process.
Lucknow-based centers assist patients pursuing Jascayd therapy.
Bhubaneswar's institutions support access to Jascayd for eligible patients.
Guwahati's specialists help coordinate Jascayd access for patients across the Northeast.
Patients in other cities across India can also access Jascayd through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
